NM_001042723.2:c.7816T>A

CA070340

Gene: RYR1

Condition: malignant hyperthermia of anesthesia

Inheritance Mode: Autosomal dominant inheritance

UUID: 1b82822c-ead8-46e0-85e0-ea89a489156d

Approved on: 2021-12-21

Published on: 2021-12-21

HGVS expressions

NM_001042723.2:c.7816T>A
NC_000019.10:g.38502708T>A
CM000681.2:g.38502708T>A
NC_000019.9:g.38993348T>A
CM000681.1:g.38993348T>A
NC_000019.8:g.43685188T>A
NG_008866.1:g.74009T>A
ENST00000359596.8:c.7816T>A
ENST00000355481.8:c.7816T>A
ENST00000359596.7:n.7816T>A
ENST00000360985.7:c.7813T>A
ENST00000594335.5:n.1268T>A
NM_000540.2:c.7816T>A
NM_001042723.1:c.7816T>A
NM_000540.3:c.7816T>A

Likely Benign

The Expert Panel has overridden the computationally generated classification - "Uncertain Significance - Insufficient Evidence"

• Met criteria codes: BS2

• Not Met criteria codes: PS3 PS4 PP3 PM1 BP4

Expert Panel

Malignant Hyperthermia Susceptibility VCEP

Criteria Specification Information

Evidence submitted by expert panel

Malignant Hyperthermia Susceptibility VCEP

This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of cysteine with serine at codon 2606 of the RYR1 protein, p.(Cys2606Ser). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.000009, a frequency consistent with pathogenicity for MHS. This variant has been reported in an individual with a personal or family history of an MH episode and a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), however, this individual had a second variant of uncertain significance in RYR1, p.(Ala1372Val), PS4 was no implemented (PMID:30236257). This variant has been identified in four related individuals with negative IVCT results, BS2_Moderate (PMID:30236257). Functional studies identified for this variant did not fulfill PS3 as defined by the MHS-RYR1 VCEP (PMID:21603587). This variant does not reside in a hotspot for pathogenic variants that contribute to MHS. A REVEL score of 0.818 supports neither a pathogenic nor a benign status for this variant. Based on using Bayes to combine criteria this variant is assessed as Likely Benign, (PMID: 29300386). Criteria implemented: BS2_Moderate.

Met criteria codes

• BS2: Identified in four related individuals with negative IVCT results, BS2_moderate (PMID:30236257).

Not Met criteria codes

• PS3: Functional studies identified for this variant did not fulfill PS3 as defined by the MHS-RYR1 VCEP (PMID:21603587).
• PS4: This variant has been reported in an individual with a personal or family history of an MH episode and a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), however, this individual had a second variant of uncertain significance in RYR1, p.(Ala1372Val), PS4 was no implemented (PMID:30236257).
• PP3: A REVEL score of 0.818 supports neither a pathogenic nor a benign status for this variant.
• PM1: This variant does not reside in a hotspot for pathogenic variants that contribute to MHS.
• BP4: A REVEL score of 0.818 supports neither a pathogenic nor a benign status for this variant.